Cancer screening is a detecting a cancer before the sign appears. It includes DNA tests, blood tests, urine tests, and other tests. It is mainly many types such as cervical cancer, colorectal cancer, head & neck cancer, breast cancer, prostate cancer, lung cancer and skin cancer etc. Cervical cancer includes Pap test and Human papillomavirus (HPV). Colorectal cancer includes sigmoidoscopy test, stool DNA test, double contrast barium enema, fecal occult blood test (FOBT) and colonoscopy test. Prostate cancer includes Prostate-specific antigen (PSA) test and Digital rectal examination (DRE). The major risks associated with cancer screening techniques are false reassurance, false positives, over diagnosis and increased testing.
According to study, “Cancer Screening Market in China (2018-2023)” some of the major companies that are currently working in the cancer screening market in China are F. Hoffmann-La Roche AG, Quest Diagnostics, Qiagen, Abbott Laboratories, Hologic Inc.
Based on tests, the cancer screening market is segmented into genomic testing, imaging, digital pathology, cancer biomarker tests, biopsy and endoscopy etc. Imaging tests include Computed Tomography (CT) scan, ultrasound, Positron Emission Tomography (PET) scan, mammography and Magnetic Resonance Imaging (MRI) scan. Cancer biomarker tests include prostate specific antigen tests, EGFR mutation tests, Alpha Fetoprotein (AFP) test, HER2 test, Circulating Tumor Cells (CTC) tests, Cancer Antigen tests (CA 19-9 and CA 125), BRCA tests and other tests such as CEA tests, ALK tests and KRAS mutation tests.
The China cancer screening is mainly driven by increase in the aging population followed by adoption of innovative screening technologies, increasing number of bio pharmaceutical companies, growing research & development, rapid rise in the number of cancer cases, growing attentiveness among people, rising adoption of high-scale investments, advent of efficacious genetic tests, rising favourable government policies, potential product pipeline, increase in the patient pool. However some of the restraints are lack of screening guidelines, inadequate healthcare access and high screening tests costs.
The drugs at inferior prices along with ensuring affordability and accessibility are expected to be a major threat in the country. The people of country demand a transparency as provision of perfect & proper treatment to big opportunity for this market. Nowadays, the government is focusing on several cancer control programs for alleviating cancer prevalence. These programs include prevention, early diagnosis & treatment. Early diagnosis programs contain screening for cervix & breast cancer while prevention programs contain anti-smoking operations and immunization against hepatitis. The Cancer Screening Program in Urban China (CanSPUC) is a government initiated program for assessing the continuing sustainability of cancer screening in country.
In the past decade, China’s demand for cancer screening has developed at a rapid pace. Cancer is one of the most important healthcare burdens in country. The Chinese economy preserves a high pace of augmentation stimulated by the consecutive enhance in capital venture. Lung cancer screening holds largest market share in region, which is mainly driven by adult males. It is expected that the China cancer screening market will be reached US $1.5 billion, at a CAGR of 14 %, by 2023. In the near future, it is predicted that the market to grow rapid pace owing to massive impact of rising cancer diseases by tobacco.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications